# SEC 8-K Summary: Athena Technology Acquisition Corp. II On September 10-11, 2026, Athena Technology Acquisition Corp. II held a special stockholder meeting and obtained overwhelming approval (99.86% quorum with unanimous or near-unanimous votes) for its business combination with Ace Green Recycling Inc., including approval of the merger agreement, amended charter, new board of six directors, and a 2026 Equity Incentive Plan. The company simultaneously extended its deadline to complete the business combination by one month, from September 14 to October 14, 2026, marking the fourth of nine permitted monthly extensions and indicating the transaction remains pending. Only 9,029 shares were redeemed by stockholders, representing minimal dissent and suggesting strong investor confidence in the deal. This filing signals the transaction is progressing toward imminent closing, though investors should note the repeated need for deadline extensions may raise questions about deal completion certainty.

# bioAffinity Technologies, Inc. (BIAF) - 8-K Summary bioAffinity Technologies filed a Form 8-K on September 11, 2026, disclosing that management prepared presentation materials for use at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16, 2026). The presentation materials were furnished as Exhibit 99.1 but were explicitly not "filed" under securities laws, meaning they are not subject to liability provisions and will not be incorporated into other SEC filings. This is a routine disclosure of investor relations activities with minimal material impact, as the company is simply announcing its participation in a widely-attended institutional investor conference where it will discuss operations and performance.

# Summary of Opus Genetics 8-K Filing Opus Genetics issued a corrected version of its clinical data presentation on September 11, 2026, addressing an immaterial translation error in logMAR visual acuity measurements from its Phase 1/2 trial of OPGx-BEST1 for BEST1-related retinal diseases. The revision corrects visual acuity changes at the 3-month mark across five trial participants in Cohort 1, with results ranging from 12-letter improvements to 10-letter declines depending on the participant and eye treated. The company added high-resolution microperimetry grid images to provide additional detail on individual loci data. This correction appears procedural and does not indicate material changes to trial outcomes, though investors should review the revised presentation to assess whether the corrected data strengthens or weakens the clinical profile of this gene therapy candidate.

# Digital Brands Group, Inc. - 8-K Summary Digital Brands Group, Inc. (NASDAQ: DBGI) issued an investor update on September 10, 2026, announcing details on a $165 million two-year binding contract for its U.S. Program to supply apparel, footwear, and toiletries to workforce re-entry programs serving 771,481 U.S. residents. The company has already secured $3.3 million in guaranteed cash flow through December 31, 2026, from the first two markets of the program, with projected cash flow margins of 15-18%. Additionally, the company provided a status update on its go-private strategic review process, with a 60-day "go-shop" period ending October 5, 2026, during which shareholders can solicit alternative acquisition proposals. This filing is a Regulation FD disclosure providing operational and strategic updates rather than announcing material adverse events, indicating ongoing contract execution and potential corporate restructuring considerations.

# Summary of DFDV 8-K Filing (September 11, 2026) DeFi Development Corp. entered into an at-the-market (ATM) sales agreement with R.F. Lafferty & Co., Inc. to offer up to 30 million shares of its Variable Rate Series C Perpetual Preferred Stock (CHAD) at a commission of 0.75%. The company increased authorized CHAD shares from 2.2 million to 32.2 million on September 8, 2026 to support this offering. Proceeds will be used for general corporate purposes, working capital, acquiring Solana (SOL) digital assets, and strategic initiatives. This dilutive offering gives the company significant capital-raising flexibility through an ATM structure, though investors face potential share dilution and the company has no obligation to issue shares while retaining full discretion over timing and pricing.

# CEA Industries Inc. (BNC) – 8-K Summary CEA Industries Inc. issued a press release on September 11, 2026, announcing financial and operational results for the fiscal quarter ended July 31, 2026. The 8-K filing itself contains no material details regarding the company's performance, financial condition, or business developments—only a reference to the attached press release (Exhibit 99.1). Without access to the actual press release content, the specific financial metrics, operational changes, and investor impact cannot be determined from this filing alone. Investors should review the full press release for details on revenue, earnings, guidance, and any significant business events affecting the company's outlook.

# Gen Digital Inc. (GEN) 8-K Summary Gen Digital held its 2026 Annual Meeting of Stockholders on September 9, 2026, with mixed voting outcomes. All nine board nominees were successfully re-elected, and KPMG LLP was ratified as the independent auditor for fiscal 2027. However, shareholders rejected the company's executive compensation proposal in an advisory "say-on-pay" vote, with 307.1 million votes against versus 209.9 million votes in favor, indicating significant investor dissatisfaction with compensation policies. The failed say-on-pay vote is a material governance event that signals investor concerns about executive pay alignment and will require management engagement with shareholders to address compensation structure issues in future planning cycles. While this vote is non-binding, it puts direct pressure on the Compensation Committee to reassess and potentially restructure executive compensation arrangements.

# Butler National Corporation 8-K Summary Butler National Corporation announced its financial results for the quarter ended July 31, 2026 on September 11, 2026, though the specific financial metrics are contained in the attached press release rather than detailed in the 8-K itself. The filing provides limited material information beyond confirming earnings release disclosure, which is standard quarterly reporting activity. As the company has no securities registered on major exchanges (as indicated by "None" in the trading symbol section), this filing has minimal direct impact on public market investors. The interim CEO and CFO signature suggests potential recent leadership transitions, which warrants investor attention regarding management stability and strategic direction.

# Cardlytics, Inc. (CDLX) 8-K Summary Cardlytics settled a material indemnification dispute with Amit Jain, founder and former CEO of acquired company Bridg, for $6.4 million on September 4, 2026. The settlement covers Jain's portion of a prior DailyGobble litigation settlement (~$5.3 million) plus associated legal fees (~$1.1 million), which aligns with the company's existing $6.5 million accrual as of June 30, 2026. This settlement eliminates a significant contingent liability that stemmed from Cardlytics' 2021 acquisition of Bridg and the indemnification obligations it assumed. The company is pursuing insurance reimbursement to offset portions of this cost, which could reduce the net financial impact to shareholders.

# FiEE, Inc. 8-K Summary FiEE, Inc. disclosed that David Natan, a Board member and Chair of the Audit Committee, will resign effective September 30, 2026, citing no disagreement with company operations or policies. Natan also held membership on the Compensation Committee and Nominating and Corporate Governance Committee, meaning his departure will create vacancies in multiple board committees. The Nominating and Corporate Governance Committee has initiated a search for a successor director, with the appointment to be announced in a future 8-K filing. For investors, this change may impact board governance oversight, particularly audit committee functions, until a replacement is appointed and committee assignments are finalized.

# Coffee Holding Co., Inc. – 8-K Summary Coffee Holding Co., Inc. (Nasdaq: JVA) issued a press release on September 11, 2026, disclosing financial results for the quarter ended July 31, 2026. The filing itself provides no specific operational or financial metrics, instead referring investors to an attached press release (Exhibit 99.1) for details on quarterly performance. The company explicitly notes that the information is not "filed" under SEC regulations and will not be incorporated into future filings unless expressly referenced. Without access to the actual press release content, investors cannot assess the materiality of the results or their impact on the company's financial condition from this 8-K filing alone.

# SEC 8-K Summary: Greenwave Technology Solutions, Inc. Greenwave Technology Solutions closed a $3.75 million private placement of Series B Convertible Preferred Stock to five institutional investors on September 9, 2026. The company issued 3,750 shares of Series B Preferred Stock convertible into common stock at an initial conversion price of $5.24 per share. The preferred stockholders received significant protective provisions, including veto rights over major corporate actions (amendments to charter/bylaws, creation of senior preferred stock, share repurchases, and dividend payments) and a 4.99% ownership blocker on conversions. This capital infusion provides liquidity but subordinates existing common shareholders and gives new preferred investors substantial governance control through blocking rights on key corporate decisions.

# SEC 8-K Filing Summary: Shuttle Pharmaceuticals Holdings, Inc. On September 9, 2026, Shuttle Pharmaceuticals Holdings, Inc. held a Special Meeting of Stockholders where shareholders approved five proposals, including authorization to issue approximately 17.8 million shares of common stock and pre-funded warrants related to a merger with United Dogecoin Inc. and a separate securities purchase agreement, both requiring Nasdaq Listing Rule 5635 approval. Shareholders also approved an amendment to increase the equity incentive plan share authorization to 8.8 million shares and voted to change the company's name to United Compute Inc. The company achieved a 57.33% quorum with all proposals passing by comfortable margins, indicating strong shareholder support for the transformational transactions and corporate restructuring. For investors, these approvals enable the completion of previously announced merger and investment transactions, though the substantial share dilution (potentially 17.8+ million new shares from conversions and warrant exercises) will significantly impact existing shareholders' ownership percentages.

# SEC 8-K Summary: Greenland Mines Ltd. On September 8, 2026, Greenland Mines Ltd. (NASDAQ: GRML) announced two board resignations and one new appointment with no material operational concerns. Directors Shalom Hirschman and Riad El-Dada resigned without disagreement over company matters, and the board appointed Jason Hawkins to fill a vacant seat. Hawkins brings significant capital markets expertise with 25+ years in investment and merchant banking, including experience raising financing for mining and precious metals companies, and currently serves as Chairman and CEO of Intrusion Precious Metals Corp., a significant minority shareholder in Greenland Mines. This appointment suggests continuity in the company's financing and strategic direction, particularly relevant given the company's focus on mining operations.

# Cronos Group Inc. (CRON) 8-K Summary Cronos Group announced on September 8, 2026, that it has amended its Share Sale and Purchase Agreement for the acquisition of CanAdelaar B.V., a licensed Dutch cannabis grower, by extending the transaction's Long Stop Date from September 9, 2026, to October 15, 2026. This one-month extension provides additional time to satisfy closing conditions for the acquisition of one of ten licensed operators in the Dutch Controlled Cannabis Supply Chain Experiment. The amendment does not alter other terms of the original agreement signed in December 2025, and the transaction remains on track to close within the newly extended timeframe. For investors, this delay suggests potential regulatory, financing, or operational hurdles that required additional time but does not indicate fundamental problems with the deal structure or Cronos's strategic direction in European cannabis markets.

# SEC 8-K Summary: Lithium Americas Corp. Lithium Americas Corp. announced the retirement of Alexi Zawadzki, Vice President of Corporate Development, effective September 11, 2026. The departure is routine and non-contentious, with no disagreements cited regarding company operations, policies, or practices. This is a minor personnel change with limited material impact on the company's operations or investor interests, as it involves a mid-level executive position rather than senior leadership. No replacement announcement or succession plan was disclosed in this filing.

# Summary of Sphere 3D Corp. 8-K Filing Sphere 3D Corp. completed a private placement on September 11, 2026, raising approximately $5.0 million through the issuance of 1,666,661 units to accredited investors, with each unit consisting of one common share and one warrant exercisable at $3.50 per share. The company intends to use net proceeds for working capital and general corporate purposes, with potential additional gross proceeds of approximately $5.8 million if all warrants are exercised for cash. Company insiders, including the Chairman and CEO, participated in the offering, purchasing approximately $1.0 million of the 1,666,661 units. The securities are subject to a six-month lock-up period from closing, and the company must file a registration statement on Form S-3 within 181 days to enable resale of the securities. This dilutive financing may pressure existing shareholders but provides the company with needed liquidity for operations.

# Coty Inc. 8-K Summary Coty Inc. announced a leadership transition in which Laurent Mercier stepped down as Chief Financial Officer on September 1, 2026, to become Strategic CEO Advisor through June 30, 2027, while Soraya Benchikh assumes the CFO role. Under the transition agreement, Mercier will receive his annual base salary of €825,000 through the transition period, with a one-time bonus of €290,000, but is ineligible for annual bonuses or variable compensation for fiscal 2026-2027. The arrangement includes provisions allowing Mercier to accelerate his departure date to December 20, 2026, with a lump-sum payment, along with post-transition non-competition covenants and contractual severance benefits. This orderly management succession should provide continuity during the CFO transition while managing costs through restricted bonus eligibility and potential early departure options.

# Summary of Reliance Global Group, Inc. Form 8-K Filing On September 4, 2026, Reliance Global Group, Inc. (NASDAQ: EZRA) amended its credit agreement with Oak Street Funding LLC to permit the sale of its wholly owned subsidiary Southwestern Montana Insurance Center (SMI), with $1,207,324.67 in proceeds (50% of total sale proceeds) applied to loan repayment rather than the customary full amount. This modification allows the company to retain the remaining sale proceeds while Oak Street releases SMI as a borrower and relinquishes all security interests in SMI's assets upon receiving the loan paydown. The amendment, which included a $15,000 fee, was consented to by all guarantors including CEO Ezra S. Beyman and affiliated entities, and is effective as of September 4, 2026. For investors, this transaction provides modest debt reduction and improved liquidity, though it signals the company's ongoing need to monetize assets to manage its debt obligations and capital structure.

# BioRestorative Therapies (BRTX) 8-K Summary BioRestorative Therapies' Vice President of Research and Development, Mr. Silva, resigned effective immediately on September 4, 2026, claiming "Good Reason" under an employment agreement dated June 2026 and asserting that a "Change in Control" occurred due to Board composition changes tied to a June 2026 loan agreement with Bowery Group LLC. Silva is demanding approximately $1.29 million in severance, accelerated equity awards, and benefits continuation. However, the Board has explicitly rejected the validity of the employment agreement and the characterization of a Change in Control, reserved all rights and defenses, and directed special counsel to investigate the circumstances surrounding this and related executive employment agreements with former officers. Pending investigation completion, the Company will only pay accrued base salary and legally required amounts, creating material litigation risk for investors regarding potential executive severance obligations.

# GlucoTrack, Inc. (GCTK) - 8-K Summary On September 10, 2026, GlucoTrack, Inc. raised $4.5 million in gross proceeds through a private placement of senior secured convertible notes totaling $11.6 million principal (reflecting a 22% discount) and accompanying warrants. The financing involved both cash injection ($4.5 million) and a refinancing of existing convertible debt ($4.5 million principal exchanged). The new notes carry 8% interest (18% upon default), mature in 9 months, and are convertible into common stock at prices ranging from $0.624 to $3.12 per share, with investors also receiving warrants exercisable at $7.50/share for five years. **Key investor impacts include:** (1) significant dilution risk—the combined securities are subject to a 19.99% exchange cap unless stockholders approve greater issuance; (2) aggressive timelines—the company must file a registration statement within 10 days and achieve effectiveness within 45 days or face penalty share issuances up to $1.5 million; and (3) near-term maturity pressure with 9-month repayment obligation. The financing structure suggests liquidity challenges and positions investors with substantial equity upside but reflects the company's constrained financial position given the heavy discounting and secured debt status.

# Summary of Rent the Runway, Inc. 8-K Filing Rent the Runway announced a $15 million rights offering on September 11, 2026, with a backstop agreement ensuring full funding by an investor group comprising CHS US Investments LLC, Gateway Runway, LLC (Nexus), and S3 RR Aggregator, LLC (STORY3). Existing Class A common shareholders will receive transferable subscription rights to purchase additional shares at a price equal to the greater of $3.55 or the 15-day volume-weighted average price through the record date. The investor group has committed to purchase any unsubscribed shares, guaranteeing the company completes the fundraising contingent on SEC registration statement approval. This capital raise appears aimed at addressing liquidity needs and improving financial flexibility for the emerging growth company.

# Lipocine Inc. (LPCN) - 8-K Summary On September 8, 2026, Lipocine Inc. agreed to adjust the sales agent fee under its existing at-the-market (ATM) offering agreement with A.G.P./Alliance Global Partners to up to 3.0%, subject to further adjustment by mutual consent. This modification to the Sales Agreement originally dated April 26, 2024 represents a material change to the company's cost structure for raising capital through equity offerings. The adjustment may impact future dilution to shareholders and the company's net proceeds from any equity raises conducted under this facility. For investors, this primarily signals the company's continued reliance on ATM offerings for liquidity and potential upcoming capital needs, though the specific prior fee rate is not disclosed, making it unclear whether this represents an increase or decrease in costs.

# Summary of HWH International Inc. 8-K Filing (September 11, 2026) HWH International Inc. entered into a material stock purchase agreement to acquire Hearty Nova Limited from majority shareholder Smart Dynamics Technology Limited for $1.00, gaining a 51% stake in a Hong Kong joint venture (China Gas Africa Clean Energy Investment Holdings Limited) that plans to develop a natural gas processing plant in Nigeria, with the company committing approximately $1.17 million in anticipated investments. The transaction involves significant related-party relationships, as the company's Chairman Liu Ming Hui owns Smart Dynamics and holds substantial stakes in the joint venture partner, raising potential governance concerns for investors. Separately, HWH has resolved its Nasdaq compliance issue regarding the minimum stockholders' equity requirement ($2.5 million threshold under Listing Rule 5550(b)(1), which it previously failed to meet with only $2.08 million as of March 31, 2026); through two capital raises totaling $10.5 million completed by August 2026, the company now reports stockholders' equity of approximately $12.8 million and received conditional compliance confirmation from Nasdaq on August 28, 2026, though Nasdaq warned it will continue monitoring and may pursue delisting if compliance lapses at the next periodic report. The company also announced a planned name change to "EnerSyn Global Inc." to reflect its strategic expansion into energy and natural resources sectors.

# SEC 8-K Filing Summary: Intelligent Bio Solutions Inc. **Company:** Intelligent Bio Solutions Inc. (NASDAQ: INBS) **Date:** September 10, 2026 Intelligent Bio Solutions reported a shares outstanding update, with total common stock increasing to 3,316,803 shares as of September 10, 2026, due to two events: the exercise of 285,000 prefunded warrants and the issuance of 4,333 restricted shares under an Investor Relations advisory agreement dated February 2024. This filing is routine administrative disclosure with no material adverse business developments announced. The warrant exercise and restricted share issuance represent modest share count dilution but do not indicate operational challenges or significant strategic changes for the biotech company.

# Apimeds Pharmaceuticals US, Inc. – 8-K Summary On September 10, 2026, Apimeds Pharmaceuticals US, Inc. amended its April 2026 settlement agreement with the Inscobee Parties and other stakeholders, restructuring its board of directors to include significant governance controls. The interim board will comprise four directors (including Elona Kogan, Carol O'Donnell, Dr. Bennett Weintraub, and Sungjoon Chae), with none removable without written consent from Dr. Vin Menon and the Inscobee Parties. Following a future "Preferred Stock Conversion," the board will expand to seven members with four independent directors nominated by MindWave, two nominees from Menon, and Chae. Sungjoon Chae, the company's Co-CEO since May 2026, was simultaneously appointed as a director. This governance restructuring effectively concentrates control among specific stakeholders and limits management autonomy, which may indicate ongoing disputes or protective measures for investors in the settlement agreement but could also signal instability in corporate governance that warrants investor scrutiny.

# Summary of Skye Bioscience 8-K Filing (September 8, 2026) Skye Bioscience announced three material developments: (1) the resignation of CFO John P. Sharp, with CEO Punit Dhillon assuming the principal financial and accounting officer role while maintaining his other positions; (2) termination of the Master Services Agreement with Lohman & Associates, Inc., which supported Sharp's CFO functions; and (3) **regained compliance with Nasdaq's minimum bid price requirement** (Nasdaq Listing Rule 5550(a)(2)), as the stock closed at or above $1.00 per share for 10 consecutive business days. The filing also references an ongoing proposed acquisition of Redx Pharma Limited, with a proxy statement expected to be filed for stockholder approval. For investors, the restoration of Nasdaq compliance removes delisting risk, while the CFO transition presents continuity considerations given Dhillon's expanded responsibilities managing both executive and financial reporting functions.

# Summary of NET Power Inc. 8-K Filing (September 8, 2026) NET Power Inc. has indefinitely suspended its utility-scale oxy-combustion development and commercialization arrangements with Baker Hughes affiliates (Nuovo Pignone entities) through three integrated suspension and amendment agreements executed on September 8, 2026. The suspension affects the Joint Development Agreement, Commercial Agreement, and related licensing arrangements, though these agreements remain valid and can be reinstated by mutual consent. Specifically, Baker Hughes lost exclusive access to NET Power's La Porte, Texas demonstration facility, and no royalty obligations or deployment commitments have been agreed upon going forward. The suspension reflects changing market and economic conditions making utility-scale oxy-combustion power generation uneconomical at present, and does not result from any breach or default by either party. Importantly, the suspension only affects NET Power's oxy-combustion business arrangements and does not impact other commercial arrangements such as Project Permian. For investors, this signals a strategic pivot away from utility-scale commercialization efforts, potentially reducing near-term revenue opportunities but preserving optionality to revive these partnerships if market conditions improve.

# America's Car-Mart, Inc. (CRMT) - 8-K Summary America's Car-Mart obtained a second extension of its debt covenant waiver period from lenders, extending the deadline from September 11 to September 18, 2026, as the company faces anticipated defaults on financial covenants under its credit agreement with Silver Point Finance. The company is actively pursuing strategic alternatives including financing, recapitalization, restructuring, and mergers/acquisitions, with management stating discussions remain active with third parties and lenders. However, significant uncertainty remains: there is no assurance the company will meet conditions for permanent covenant relief, achieve a successful transaction, or establish a sustainable capital structure, and investors face potential for significant or complete loss of investment through dilution or restructuring. The repeated short-term extensions underscore the company's acute liquidity pressure and the limited time remaining to execute a viable strategic outcome before additional covenant defaults occur.

# Fly-E Group, Inc. (FLYE) 8-K Summary **Material Events:** Fly-E Group announced immediate leadership changes on September 11, 2026, with CEO and Director Lisa Fan resigning (without disclosed disagreement with the board). The company appointed Qiang Chen as Chief Executive Officer and Jingxia Song as an independent director and audit committee member, both effective immediately. **Key Personnel Details:** Chen brings nearly 30 years of accounting and finance experience, including prior roles as CFO of General Steel Holdings and current CEO of a Chinese financial consulting firm; he will receive $60,000 annual compensation. Song contributes 16+ years in corporate operations and administration; she will receive $26,400 annually. **Investor Impact:** The swift executive transition signals potential strategic shifts at the company, though the non-contentious nature of Fan's departure and Chen's substantial experience in finance and public company management may provide some stability. However, the relatively modest compensation levels and reliance on new leadership warrant monitoring for any operational or financial changes in upcoming quarterly filings.

# Q/C Technologies 8-K Summary On September 10, 2026, Q/C Technologies (NASDAQ: QCLS) terminated two material consulting agreements effective immediately: one with Chelsea Voss (dated January 2026) and another with Ocean Avenue Holdings LLC, an entity affiliated with Martin Shkreli (dated December 2025). Simultaneously, Chelsea Voss resigned from the company's Board of Directors, though the company stated this was not due to disagreement with operations or policies. The company provided no additional details regarding reasons for the terminations or their financial impact. Investors should note the removal of controversial affiliations, particularly the Shkreli connection, though the lack of transparency on circumstances may raise governance questions.

# reAlpha Tech Corp. (AIRE) - 8-K Summary On April 23, 2026, reAlpha Tech Corp.'s Compensation Committee approved annual restricted stock unit (RSU) grants for fiscal year 2026, with quarterly awards to executive officers: CEO Michael J. Logozzo ($75,000/quarter), CFO Thomas J. Kutzman Jr. ($68,750/quarter), and Executive Chairman Giri Devanur ($62,500/quarter), each representing 25% of their respective base salaries. The RSUs will vest 50% after 12 months from grant, with the remaining 50% vesting in equal quarterly installments over the following 12 months, contingent on continued employment. This filing was submitted inadvertently late (dated April 23, 2026 but filed September 11, 2026), and the company intends to continue similar annual RSU grants in future years at the Compensation Committee's discretion. For investors, this represents routine executive compensation aligned with historical practices, though the late filing may warrant attention to the company's operational controls and disclosure timeliness.

# SEC 8-K Summary: BONK, Inc. Preferred Stock Redemption On September 4, 2026, BONK, Inc. entered into a Preferred Stock Redemption Agreement with Core4 Capital Holdings Corp to repurchase 26,667 of Core4's 100,000 Series A Preferred Shares for $4 million, with payment due within three business days. As part of the transaction, Core4 irrevocably waived all anti-dilution rights, voting rights, liquidation preferences, and conversion rights associated with the remaining 73,333 preferred shares it will retain, while also releasing all claims against the company. This partial redemption reduces the company's preferred stock obligations while simplifying its capital structure, though it represents a significant $4 million cash outlay that may impact liquidity. The agreement is material as it eliminates future anti-dilution protections and substantially modifies Core4's ownership position and governance rights.

# Summary of NewHold Investment Corp III 8-K Filing (September 11, 2026) NewHold Investment Corp III entered into a Forward Share Purchase Agreement with an unaffiliated stockholder on September 11, 2026, whereby the seller will purchase up to 7 million Class A ordinary shares (the "Recycled Shares") at NewHold's trust account redemption price, with those shares waiving redemption rights in connection with the pending Business Combination with newcleo Ltd. NewHold will prepay the seller from its trust account at closing an amount equal to the shares purchased multiplied by the per-share redemption price, with the transaction maturing within 24 months or earlier at the counterparty's option or seller's discretion. The forward purchase agreement includes provisions for optional early termination by the seller (with cash settlement at a reset price, initially equal to the initial price), and final settlement can be either physical (if shareholder approval and distributable reserves exist) or cash-based depending on conditions at maturity. This transaction effectively locks in share recycling ahead of the pending newcleo business combination, reducing redemption risk and ensuring funding availability while subordinating the seller's redemption rights to support the deal's financing structure.

# Summary of Caring Brands, Inc. 8-K Filing (September 11, 2026) Caring Brands, Inc. completed a second closing of its private placement on September 11, 2026, raising an additional $2.55 million by issuing 2,549.9 shares of Series B Convertible Preferred Stock and warrants to purchase approximately 5.1 million common shares. Combined with the initial closing completed on September 1, 2026, the company has now raised $7.15 million of its targeted $11 million offering, with additional subscription commitments of $4.4 million pending. The capital raise is material because it directly addresses Caring Brands' Nasdaq delisting risk: the company had been notified in April 2026 that it failed to maintain the minimum $2.5 million stockholders' equity requirement, and received a delisting determination in July 2026. Pro forma financial statements indicate the completed private placement would result in stockholders' equity of $8.22 million, exceeding the compliance threshold. However, Nasdaq will continue monitoring compliance through the company's next quarterly report (Q3 2026), and the company risks delisting if it fails to maintain the minimum equity requirement at that time. For investors, successful completion of additional closings and sustained compliance are critical to maintaining the company's Nasdaq listing.

# Summary of Sunshine Biopharma Inc. 8-K Filing Sunshine Biopharma Inc. (NASDAQ: SBFM) reported that the exercise price of its outstanding Series B Warrants has been reduced to $1.2046 as of September 11, 2026, due to recent common stock sales under its at-the-market (ATM) offering. This reduction reflects a downward adjustment mechanism built into the Series B Warrants that is triggered by below-market equity issuances, making the warrants more valuable to holders as they can now exercise at a lower strike price. The adjustment may continue to occur with future stock sales under the ATM offering, subject to the warrant terms. For investors, this indicates ongoing dilution from the company's capital raising activities and suggests the stock price may be trading at levels that trigger warrant anti-dilution protections, which could further dilute existing shareholders if warrants are exercised.

# Amesite Inc. (AMST) 8-K Summary Amesite Inc. filed an 8-K on September 11, 2026, disclosing that management has prepared presentation materials for use at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16, 2026). The presentation materials are attached as an exhibit but are furnished for disclosure purposes only and are not incorporated into SEC filings. This is a routine disclosure filing with minimal material impact; the company is simply notifying investors of presentations that will be made at a public investment conference. No significant business developments, financial results, or corporate events are announced in this filing.

# Summary Nautilus Biotechnology, Inc. entered into a new $125 million "at the market" (ATM) equity offering agreement with TD Securities (USA) LLC on September 11, 2026, replacing a prior unused ATM facility from February 2024. Under this agreement, the company can sell shares opportunistically over time at market prices, with TD Cowen receiving a 3.0% commission on proceeds sold. The offering provides Nautilus with flexible capital-raising optionality without immediate dilution, as the company has no obligation to sell shares and can suspend the program at any time. While this demonstrates management's intent to strengthen the balance sheet and fund operations, investors should note that actual share issuance will dilute existing shareholders, with the timing and extent dependent on market conditions and management discretion.

# Banzai International, Inc. - 8-K Summary Banzai International, Inc. entered into a Securities Purchase Agreement on September 4, 2026, to raise capital through a private placement of a convertible promissory note and warrants. The company issued an initial $1.5 million convertible note (expandable to $3.57 million across three tranches) with a 30% original issue discount, 10% interest rate, and conversion price of $2.75 per share, along with warrants to purchase up to 1.3 million shares at the same price. The transaction imposes significant restrictions on the company, including mandatory stockholder approval within 60 days to authorize issuance of over 20% of outstanding shares, a 50% prepayment requirement from future non-qualified financings, and automatic acceleration of the note upon qualified public offerings or delisting from Nasdaq. These terms substantially dilute existing shareholders and constrain the company's operational and financing flexibility, while the default provisions (including an automatic 20% principal increase and anti-dilution warrant adjustments) create material downside risks if the company encounters financial difficulties.

# SEC 8-K Summary: DeFi Development Corp. (DFDV) **Material Events:** On September 11, 2026, DeFi Development Corp. entered into an at-the-market (ATM) sales agreement with R.F. Lafferty & Co., Inc. to offer up to 30 million shares of its Variable Rate Series C Perpetual Preferred Stock (CHAD). The company increased authorized CHAD shares from 2.22 million to 32.2 million on September 8, 2026 to support this offering. Net proceeds will fund general corporate purposes, working capital, acquisition of Solana (SOL) digital assets, and strategic initiatives. **Investor Impact:** This offering represents significant dilution potential for existing shareholders, particularly given the substantial increase in authorized preferred shares. The 0.75% sales commission and use of proceeds for digital asset acquisitions signal the company's focus on crypto/blockchain investments. Investors should note this is a flexible ATM program with no minimum sales requirement, meaning dilution could occur gradually and opportunistically at management's discretion.

# SEC 8-K Summary: Daré Bioscience, Inc. On September 10, 2026, Daré Bioscience's board of directors approved an amendment to its bylaws reducing the stockholder meeting quorum requirement from a majority of outstanding voting shares to one-third of outstanding voting shares. This change, effective immediately, makes it easier for the company to conduct stockholder meetings by lowering the participation threshold needed to achieve a valid quorum. While this streamlines corporate governance and meeting logistics, it could potentially enable major decisions to proceed with less widespread shareholder participation, which may be viewed as reducing minority shareholder influence depending on investor perspective.

# Summary of Nauticus Robotics 8-K Filing Nauticus Robotics received notice on September 9, 2026 that an institutional investor (ATW Special Situations II, LLC) exercised its contractual right to extend the maturity date of $3.985 million in Original Issue Discount Senior Secured Convertible Debentures by one year, from September 9, 2026 to September 9, 2027. The extension was automatic upon the holder's delivery of notice and requires no additional fees or amendments to the underlying debt terms, with all interest, accrued damages, and conversion rights remaining intact through the new maturity date. This development provides the company additional time to meet its debt obligations without immediate refinancing pressure, though investors should note the company still faces the obligation to repay or refinance this debt within the extended timeframe. The debentures remain convertible into equity, which could result in significant dilution if conversion occurs.

# Flux Power Holdings 8-K Summary Flux Power Holdings, Inc. announced the resignation of Chief Operating Officer Jeff Mason, effective September 25, 2026. Under a separation and release agreement, Mason will receive a $5,000 severance payment within ten days of agreement execution, contingent upon signing a general release of claims against the company. The departure represents a change in executive leadership but appears relatively routine given the modest severance amount and brief notice period. Investors should monitor whether the company appoints a replacement COO and whether this departure signals any operational challenges at the battery management systems manufacturer.

# SEC 8-K Summary: Circle8 Group, Inc. On September 10, 2026, Circle8 Group, Inc. announced a preliminary, non-binding, and highly indicative proposal to acquire SThree plc (STEM.L), an international specialist STEM (Science, Technology, Engineering, Mathematics) business, through a possible cash offer. This filing serves as a Regulation FD disclosure of the company's strategic intent to expand its global IT and technology operations through this potential acquisition. Importantly, the company explicitly states there is no certainty that a firm offer will be made or regarding the terms of any such offer, indicating this is an early exploratory stage. For investors, this signals Circle8's strategic growth ambitions in the staffing and technology sectors, but the non-binding nature of the proposal presents significant execution risk and uncertainty regarding deal completion, financing, and valuation terms.

# Summary of Peraso Inc. 8-K Filing (September 8-10, 2026) Peraso Inc. announced the resignation of Chief Financial Officer James Sullivan, effective October 2, 2026, citing personal reasons with no disagreements over company operations or financial reporting. CEO Ronald Glibbery will assume the interim CFO role without additional compensation. Additionally, at the company's September 10, 2026 Annual Meeting, stockholders approved three key measures: the election of four directors, the ratification of Weinberg & Company as auditor, and an increase of 1,500,000 shares in the 2019 Stock Incentive Plan, along with approval for stock issuance to Roth Principal Investments per a June 30, 2026 agreement. The meeting achieved a 41.62% quorum with all proposals passing comfortably, though Proposal 3 (stock plan increase) showed the most opposition with approximately 36% voting against. **Investor Impact:** The CFO transition poses moderate risk if a permanent replacement takes time to find; however, the dual leadership arrangement maintains continuity. The 1.5 million share authorization dilutes existing shareholders and provides flexibility for future compensation or acquisitions, while the Roth investment approval suggests the company may need capital financing.

# SEC 8-K Filing Summary: DeFi Development Corp. (DFDV) On September 11, 2026, DeFi Development Corp. entered into an at-the-market (ATM) sales agreement with R.F. Lafferty & Co., Inc. to offer up to 30 million shares of its Variable Rate Series C Perpetual Preferred Stock (CHAD), with the company retaining discretion on timing and volume of sales. The company will pay the sales agent a commission of up to 0.75% of gross proceeds and intends to use net proceeds for general corporate purposes, working capital, acquiring Solana digital assets, and strategic initiatives. To support this offering, the company increased authorized CHAD shares from 2.22 million to 32.2 million on September 8, 2026. This ATM arrangement provides DFDV capital-raising flexibility without immediate dilution, though investors should note the potential for significant future share dilution depending on how many shares are ultimately sold under the agreement.

# SEC 8-K Summary: Quetta Acquisition Corporation Quetta Acquisition Corporation, a SPAC trading on Nasdaq, deposited $60,000 into its trust account on August 10, 2026, to fund a one-month extension of its business combination deadline from September 10 to October 10, 2026. This extension payment allows the company additional time to identify and complete its initial business combination before facing potential liquidation. The filing indicates the SPAC remains in the early stages of its acquisition process and has not yet announced a target company. For investors, this extension provides more runway for management to negotiate a deal but also signals that no definitive agreement was reached by the original deadline, which may impact shareholder confidence in the transaction's likelihood.

# Summary of Columbus Acquisition Corp 8-K Filing Columbus Acquisition Corp (NASDAQ: COLA) adjourned its Extraordinary General Meeting scheduled for September 10, 2026, without voting on the proposed business combination with WISeSat.Space Corp. The Chairman exercised authority to adjourn the meeting, and the company will announce a new meeting date and extended redemption deadline in the coming days. As of September 8, 2026, approximately $10.66 per share remained in trust. Shareholders may still exercise redemption rights by the extended deadline, and those who have already voted or submitted proxies can revise or revoke them according to procedures outlined in the original proxy statement. This adjournment delays the SPAC merger but allows shareholders additional time to make redemption and voting decisions.

# SEC 8-K Summary: MEVO Global Acquisition Corp II On September 9, 2026, MEVO Global Acquisition Corp II announced significant leadership changes: Stephen M. Silver resigned immediately as Chief Executive Officer, Chairman, and Director, while Ashley Zumwalt-Forbes was appointed as the new CEO and Chair, continuing her existing roles as COO and board member. The company stated that Silver's resignation was not due to any disagreement regarding operations, policies, or practices. Zumwalt-Forbes, age 36, has been with the company since August 2025 as COO and joined the board in December 2025; notably, she and her husband hold membership interests in the company's sponsor, Evolution Sponsor Holdings LLC II, creating potential related-party considerations. No new compensation arrangements were disclosed in connection with her appointment, though the board may still act to fill the board vacancy created by Silver's departure.

# TScan Therapeutics, Inc. (TCRX) – 8-K Summary On September 8, 2026, TScan Therapeutics' Compensation Committee approved a retention program for key employees, including CEO Gavin MacBeath and Chief Legal Officer Zoran Zdraveski, aimed at retaining talent during what appears to be a critical phase for the company. The program provides $822,000 and $416,000 in cash awards to MacBeath and Zdraveski respectively (split between November 2026, February 2027, and upon achievement of clinical milestones), plus equity grants of 2.4 million and 1.05 million RSUs respectively that vest upon financing and subsequent anniversaries. This retention structure signals that the company faces potential cash constraints and is tying executive compensation to achieving both financing and clinical milestones for its in vivo solid tumor program, suggesting upcoming capital needs and execution risks that could materially impact shareholders.

# Medicus Pharma Ltd. 8-K Summary On September 4, 2026, Medicus Pharma Ltd. issued approximately 8.53 million restricted common shares to officers and employees as equity compensation in lieu of $1.45 million in cash bonuses, valued at $0.1705 per share. The issuance was exempt from SEC registration under Section 4(a)(2) as a private transaction. This equity-for-cash bonus structure increases share dilution for existing shareholders but preserves company cash, which may be material for a smaller biotechnology firm on the NASDAQ Capital Market. Investors should note the significant dilution from this single equity grant and monitor the company's cash position and burn rate going forward.

# Summary of Ribbon Acquisition Corp. 8-K Filing Ribbon Acquisition Corp. announced a rescheduling of its Extraordinary General Meeting of Shareholders from September 14, 2026 to November 14, 2026, both at 10:00 a.m. Eastern Time. The record date for voting eligibility remains February 18, 2026, and previously submitted proxies will remain valid at the rescheduled meeting unless revoked. This two-month postponement suggests the company needs additional time to prepare materials or secure sufficient shareholder support for the business combination transaction, though the specific reason for the delay is not disclosed in this filing. Investors should monitor the November 14 meeting date and any supplemental filings for details on what will be presented for shareholder approval.

# bioAffinity Technologies, Inc. - 8-K Summary bioAffinity Technologies filed an 8-K on September 11, 2026, disclosing that management prepared presentation materials for use at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16, 2026). The filing is routine in nature and does not announce any material corporate events, financial results, acquisitions, or operational changes. The presentation materials were furnished under Regulation FD Disclosure and are explicitly not incorporated by reference into other SEC filings, limiting their legal significance. This filing has minimal direct investor impact, serving primarily as a procedural disclosure requirement for investor communications at a public conference.

# Vistagen Therapeutics (VTGN) 8-K Summary Vistagen Therapeutics held its 2026 Annual Meeting of Stockholders on September 10, 2026, where shareholders voted on three routine matters. All four director nominees were elected to the Board, with Chair Jon S. Saxe receiving the strongest support (7.35 million votes for), while CEO Shawn K. Singh faced more opposition with 3.53 million votes withheld. Shareholders also approved executive compensation on an advisory basis and ratified KPMG LLP as the independent auditor for fiscal year 2027. **Investor Impact:** This filing presents standard corporate governance matters with no material business developments or red flags. The relatively higher withhold votes for two directors (Cunningham and Singh) suggest some shareholder dissatisfaction but falls short of rejection. The strong approval of the auditor ratification and compensation package indicates overall shareholder confidence, with no immediate implications for the company's operations or financial position.

# SharonAI Holdings Inc. (SHAZ) - 8-K Summary SharonAI Holdings Inc. executed a Deed of Release on September 8, 2026, restructuring co-founder Andrew Leece's role from Chief Operating Officer to Head of Strategic Partnerships, effective September 7, 2026. Under the revised agreement, Leece will receive an annual base salary of approximately $400,000 USD, a fixed short-term incentive of ~AUD$422,535, and eligibility for up to 6,416 RSUs based on performance metrics, while retaining 151,219 unvested RSUs and forfeiting all other previously granted RSUs. The employment agreement is now fixed-term through March 31, 2027, with automatic termination unless mutually extended. This transition follows David Burns' appointment as the new Chief Operating Officer on August 27, 2026, allowing Leece to focus on strategic relationships as a founder-level executive while the company moves toward operational management continuity.

# Summary of Greenland Mines Ltd. 8-K Filing Greenland Mines Ltd. announced board changes on September 8, 2026, with two directors—Shalom Hirschman and Riad El-Dada—resigning without any disagreement with the company. The company appointed Jason Hawkins to fill a board vacancy, bringing significant industry expertise with over 25 years of capital markets experience in mining and precious metals financing. Hawkins, who is Chairman and CEO of Intrusion Precious Metals Corp. (a significant minority shareholder and predecessor entity of Greenland Mines), brings relevant sector knowledge that may signal strategic direction. The appointment appears routine with no compensation arrangements disclosed, and represents a continuity of shareholder interests given Hawkins's existing substantial stake in the company.

# SEC 8-K Summary: Athena Technology Acquisition Corp. II Athena Technology Acquisition Corp. II held a special stockholder meeting on September 11, 2026, where shareholders overwhelmingly approved a business combination with Ace Green Recycling Inc. with 9,835,040 votes in favor and zero votes against (99.86% quorum). Shareholders also approved an amended and restated charter that increases authorized shares to 115 million and changes the company name to Ace Green Recycling, Inc., eliminating blank-check company provisions. All six proposed directors—including Richard Goldberg, Jeanine Wright, and Otto C. Schwethelm—were unanimously elected to the post-merger board, and a new 2026 Equity Incentive Plan was approved. The company has extended its deadline to close the business combination by one month to October 14, 2026 (the fourth of nine permitted extensions), with 9,029 shares redeemed by shareholders pending deal consummation. **Investor Impact:** The near-unanimous approval clears the path for the SPAC merger to close, transforming Athena into an operating company in the recycling sector. However, the need for multiple deadline extensions and the modest capital deposit ($271.48) suggest potential execution challenges or financing constraints that investors should monitor through closing.

# ChampionsGate Acquisition Corp Form 8-K Summary On September 11, 2026, ChampionsGate Acquisition Corp (a SPAC) announced a definitive Agreement and Plan of Merger with Futuremain Co., Ltd., a South Korean machinery safety diagnostics and engineering firm, to create a publicly listed company. Upon closing, Futuremain will become an indirect wholly-owned subsidiary of the merged entity ("Pubco"), which will trade on the Nasdaq Stock Market under a new name. The transaction requires ChampionsGate shareholder approval and will involve SEC filings of a proxy statement and Form F-4 registration statement. The deal carries typical risks including shareholder approval uncertainty, regulatory hurdles, and potential legal challenges, with no specific financial terms disclosed in this announcement.

# FingerMotion, Inc. (FNGR) - 8-K Summary FingerMotion, Inc. announced on September 3, 2026 a non-binding memorandum of understanding (MOU) with Lyken AI Computing Inc. and BlueFlare Energy Solutions Inc., along with updates on natural gas supply discussions related to its Alberta corridor development program. This filing is limited in substance—it discloses a preliminary, non-binding agreement, which carries minimal legal obligations and represents an early-stage exploration of potential partnerships. The MOU provides no financial metrics, deal terms, or timelines, leaving investors with limited visibility into the actual impact or likelihood of a material transaction. Investors should note that non-binding MOUs frequently do not progress to definitive agreements, and the lack of concrete details warrants caution regarding the significance of this development.

# Medicus Pharma Ltd. 8-K Summary On September 4, 2026, Medicus Pharma Ltd. issued 8,529,412 restricted common shares to officers and employees who elected to receive their cash bonuses ($1.45 million aggregate) in equity instead of cash, valued at $0.1705 per share. The issuance was exempt from SEC registration under Section 4(a)(2) as a private transaction. This equity compensation approach preserves cash but significantly increases share count, potentially diluting existing shareholders' ownership percentages. For investors, this represents modest immediate dilution but demonstrates management confidence in the company's future value and commitment to preserving liquidity at the emerging growth company stage.

# Toppoint Holdings Inc. (TOPP) - 8-K Summary On September 8, 2026, Toppoint Holdings Inc. held its Annual Meeting of Stockholders where investors approved five significant proposals with strong majorities (63.61% quorum). Most notably, stockholders authorized a reverse stock split of up to 1-for-900 at the Board's discretion through August 2029, approved reincorporation from Nevada to Delaware, and voted to increase authorized common shares from 300 million to 1 billion. All five board nominees were re-elected with overwhelming support, except director Jimmy M. Wong, whose term expired and was not re-nominated. The reincorporation and share authorization increase have not yet become effective pending completion of applicable filings, and the company will separately disclose when these actions take effect. **Investor Impact:** The reverse split authorization signals potential near-term stock price pressures or delisting concerns that the Board may address. The Delaware reincorporation and increased authorized shares provide flexibility for future capital raises or acquisitions but could dilute existing shareholders. The substantial authorized share increase (3.3x) combined with the reverse split option suggests the company may be preparing for significant strategic actions.

# SEC 8-K Summary: CEA Industries Inc. (BNC) CEA Industries Inc. issued a press release on September 11, 2026, announcing financial and operational results for the fiscal quarter ended July 31, 2026. However, the actual financial results and operational details are not disclosed in this 8-K filing itself—only a reference to the press release (Exhibit 99.1) is provided. The company trades on the Nasdaq Capital Market under ticker BNC, with additional securities including warrants (BNCWW, BNCWZ) and preferred stock purchase rights. Investors should review the attached press release for specific material information regarding quarterly performance, earnings, revenue, and any guidance changes that would impact the investment thesis.

# 8-K Summary: Zone Frontier Inc. Zone Frontier Inc. reported the resignation of Chief Financial Officer David Enholm, effective September 11, 2026, citing retirement as the reason. The filing explicitly states that the departure was not due to any disagreement with the company regarding operations, policies, or practices, suggesting an orderly transition. The company has not announced a replacement CFO or disclosed any interim arrangements for financial leadership. For investors, this represents a routine executive transition that should be monitored for the company's ability to promptly fill the CFO role and maintain financial reporting continuity.

# Summary of Professional Diversity Network, Inc. 8-K Filing Professional Diversity Network, Inc. (NASDAQ: IPDN) completed a 1-for-30 reverse stock split of its common stock, effective September 11, 2026, following stockholder approval at a July 2026 special meeting. The reverse split reduces the number of outstanding shares proportionally while maintaining the same authorized share count and par value, with no fractional shares issued. All equity awards, options, warrants, and convertible securities were adjusted accordingly, including common warrants issued in August 2026 that contain automatic adjustment provisions for share combination events. The stock began trading on a split-adjusted basis on the Nasdaq Capital Market on September 14, 2026, under a new CUSIP number (74312Y509). **Investor Impact:** Reverse splits typically signal a company's effort to boost per-share stock price to meet exchange listing standards or improve market perception, but do not change underlying company value. Shareholders should monitor whether IPDN achieves compliance with Nasdaq minimum bid price requirements and whether the stock price recovery sustains post-split.

# Summary of Ocean Power Technologies 8-K Filing Ocean Power Technologies, Inc. executed a **1-for-30 reverse stock split** effective September 11, 2026, reducing outstanding shares from approximately 270.1 million to 9.1 million shares. The Board selected this ratio within the stockholder-approved range of 1-for-5 to 1-for-50, with trading on a split-adjusted basis commencing September 14, 2026 on the NYSE American under a new CUSIP number. All convertible securities, options, warrants, and equity compensation plans were proportionately adjusted, while fractional shares were rounded up to the next whole share with no cash settlements. The reverse split did not trigger any acquisition or change-of-control events under the company's Section 382 Tax Benefits Preservation Plan, though the preferred stock purchase rights price adjusted from $2.25 to $67.50 per one one-thousandth of a share. **Investor Impact:** This reverse split is a defensive capital structure measure commonly used by distressed companies to restore stock price compliance or improve market perception; shareholders should monitor whether the company addresses underlying operational or financial challenges, as reverse splits alone do not create value and may signal financial stress.

# BioLargo, Inc. (BLGO) 8-K Summary BioLargo, Inc. filed a Form 8-K on September 10, 2026, disclosing that the company presented investor presentation slides at a webcast conference on that date. This is a routine disclosure under Regulation FD (Fair Disclosure) with no material operational, financial, or strategic announcements detailed in the filing itself. The actual content and any material information conveyed during the webcast would be found in the attached slide deck (Exhibit 99.1), not in the 8-K document itself. For investors, this filing is primarily administrative notification of a public presentation rather than an indication of significant corporate developments.

# T3 Defense Inc. (DFNS) - 8-K Summary T3 Defense Inc. secured a $3 million short-term loan on September 8, 2026, from an institutional lender at a high interest rate of 1% monthly (12% annualized). The note matures on the earlier of December 8, 2026, completion of a previously announced $10 million Series B Convertible Preferred Stock sale, or another financing of at least $3 million. This short maturity window and aggressive interest rate indicate the company faces near-term liquidity pressure and must execute its Series B financing or secure additional capital within three months to avoid default. Investors should note the company's reliance on completing its Series B round and monitor whether the financing materializes as planned, as failure to do so could trigger immediate repayment obligations.

# Sunshine Biopharma Inc. (SBFM) – 8-K Summary Sunshine Biopharma disclosed that the exercise price of its outstanding Series B Warrants has been reduced to $1.2046 as of September 11, 2026, due to recent common stock sales under the company's at-the-market (ATM) offering. This reduction reflects a downward adjustment mechanism built into the Series B Warrants' terms, which automatically adjusts the strike price based on equity issuances. For warrant holders, the lower exercise price makes the warrants more valuable and easier to exercise, but it also indicates the company has been issuing common shares at relatively low prices through its ATM program, which dilutes existing shareholders' ownership stakes. The disclosure is material because it signals ongoing capital raising activity and equity dilution, while potentially benefiting warrant holders at the expense of common stockholders.

# HNO International, Inc. – 8-K Summary HNO International, Inc. entered into a convertible debt financing on September 4, 2026, issuing a $210,000 principal convertible redeemable note to CFI Capital LLC with an effective purchase price of $189,000 (after a $21,000 original issue discount). The note matures September 4, 2027, carries 6% annual interest, and becomes convertible after six months at a conversion price based on 60% of the stock's lowest 20-day trading price, with additional discounts triggered by DTC "Chill" events (50%) or defaults (45%). **Investor Impact:** This financing creates significant dilution risk, with 49.3 million shares reserved for conversion—five times the expected conversion amount—at sharply discounted prices. The most-favored-nation clause and convertible structure heavily favor the creditor, and the aggressive discount percentages (down to 45%) suggest financial distress. For existing shareholders, this represents substantial near-term dilution and downward pressure on stock value, particularly if conversion occurs at the 45-50% discount levels.

# Summary of NewHydrogen, Inc. 8-K Filing On September 8, 2026, NewHydrogen, Inc. entered into a $3 million equity financing agreement with GHS Investments, LLC, featuring a "put" arrangement where the company can compel GHS to purchase shares at 92.5% of the lowest traded price over the preceding 10 trading days, with GHS receiving 112.5% of the purchase amount in shares. The agreement is conditioned on effectiveness of a Form S-1 registration statement and includes a 4.99% ownership cap on GHS, with put transactions ranging from $10,000 to $1 million each and available for 24 months or until GHS has purchased the full $3 million commitment. As an upfront commitment fee, NewHydrogen issued GHS 980,713 restricted shares (0.5% of the commitment amount), which must be registered for resale. This financing structure allows the company flexible capital access while limiting dilution through volume-based pricing caps and restricting any single investor's ownership stake, though investors should note the company must file and obtain registration statement effectiveness within 90 days to activate the financing arrangement.

# Nauticus Robotics (KITT) 8-K Summary On September 9, 2026, Nauticus Robotics received notice that an institutional investor (ATW Special Situations II, LLC) exercised its contractual right to extend the maturity date of $3.985 million in Original Issue Discount Senior Secured Convertible Debentures by one year, from September 9, 2026 to September 9, 2027. The extension was executed automatically under existing terms without requiring any amendment fees or additional consideration from the Company. The debentures remain convertible and enforceable through the extended maturity date, with all interest and other amounts continuing to accrue under the original terms, and existing guaranties and security interests remain unchanged. **Investor Impact:** This extension provides Nauticus with additional time to meet its debt obligations, reducing near-term refinancing pressure. However, it does not eliminate the underlying debt burden and signals the company may face ongoing liquidity challenges. Investors should monitor whether the company can achieve profitability or secure additional financing before the September 2027 maturity date.

# CEA Industries Inc. (BNC) - 8-K Summary On September 11, 2026, CEA Industries Inc. announced its financial and operational results for the fiscal quarter ended July 31, 2026 via press release. This is a routine quarterly earnings report filing with no material corporate events, restructuring actions, or changes to listing status disclosed. The company continues trading on the Nasdaq Capital Market under ticker BNC, with common stock, two classes of warrants, and preferred stock purchase rights outstanding. Investors should review the attached press release (Exhibit 99.1) for specific financial performance metrics and operational updates to assess any impact on the company's financial condition.

# P3 Health Partners Inc. (PIII) - 8-K Summary P3 Health Partners entered into a $70 million Securities Purchase Agreement with Chicago Pacific Founders (CPF) affiliates on September 8, 2026, to issue Series D-1 Preferred Stock units and warrants in multiple tranches. The Series D-1 Preferred Stock carries a 19.5% cumulative dividend rate, is non-convertible and non-voting, with a $100 stated value and redemption option, while the accompanying warrants are exercisable for Class A Common Stock at the Nasdaq Minimum Price with a seven-year term. CPF's ownership position is strengthened through an amended agreement granting them one additional board seat as long as they maintain 40% ownership, plus extended information rights and a standstill provision capped at 49.99% ownership through December 31, 2027. The transaction was negotiated and approved by the company's independent board committee to address related-party concerns, and the warrants are subject to a registration rights agreement for future resale of the underlying common stock.

# Visium Technologies, Inc. – 8-K Summary Visium Technologies, Inc. executed a **1-for-1,500 reverse stock split** of its common stock, effective September 11, 2026, reducing outstanding shares from approximately 1.27 billion to 846,540 shares. Simultaneously, authorized shares were reduced from 3 billion to 2 million shares, while the par value remained at $0.0001 per share. The reverse split was applied on a lot-by-lot basis with a 0.5-or-better rounding convention, resulting in 489 registered shareholders being completely eliminated (reduced to zero shares) and 64 surviving with post-split holdings. This material modification substantially consolidates shareholder positions and significantly restricts the company's ability to issue new shares during an issuance freeze period. Investors holding fewer than 750 pre-split shares received no post-split shares and received no cash compensation, effectively experiencing complete equity elimination.

# Bubblr, Inc. 8-K Summary Bubblr, Inc. is operating under receivership following a court appointment by the United States District Court for the District of Wyoming (Case No. 2:26-cv-00020-ABJ). On September 10, 2026, David A. Chetwood resigned as Chief Financial Officer, Secretary, and director, leaving the company's leadership vacant. The filing indicates the Receiver is now exercising the powers of the board of directors, suggesting the company is in financial distress and under formal judicial supervision rather than standard bankruptcy protection. This development signals significant operational challenges for investors, as receivership typically precedes asset liquidation or restructuring, with limited prospects for equity recovery.

# News Corporation (NWSA, NWS) 8-K Summary News Corporation filed this 8-K on September 10, 2026, to disclose share repurchase activity conducted under its $1 billion stock buyback authorization. The filing contains routine disclosures of daily repurchase transactions required by the Australian Securities Exchange (ASX), with supporting documentation attached as exhibits. No material changes to the company's operations, financial condition, or strategic direction are indicated in this filing. **Investor Impact:** This is a routine, non-material disclosure filing. The repurchase program itself remains unchanged at $1 billion in aggregate authorization for Class A and Class B common stock. Investors should refer to the company's quarterly and annual reports for comprehensive details on repurchase activity and financial performance.

# ANVI Global Holdings, Inc. - 8-K Summary ANVI Global Holdings has approved a 1-for-20 reverse stock split via majority shareholder written consent to address a minimum bid price deficiency on the OTCQB market, where its stock fell below $0.01 for 30 consecutive days as of June 6, 2026. The company faces delisting to the OTC Pink Open Market under OTCQB Rules Section 2.1(A) unless it meets the $0.01 minimum bid price requirement by the October 5, 2026 deadline, which management is seeking to extend by 60 days through a FINRA request. The reverse split cannot take effect until after SEC Schedule 14C clearance and FINRA approval, with implementation mechanically delayed at least 20 calendar days following the distribution of the information statement to non-consenting shareholders. This action represents a defensive maneuver after management's planned mining asset injection transaction stalled due to technical and geopolitical complications, leaving the company vulnerable to a regulatory delisting.

# SEC 8-K Filing Summary: Athena Technology Acquisition Corp. II Athena Technology Acquisition Corp. II held a special stockholder meeting on September 11, 2026, where shareholders overwhelmingly approved the business combination with Ace Green Recycling Inc. with 99.86% quorum participation and unanimous support for all major proposals. Key approvals include the merger agreement, amended and restated charter (renaming the company to "Ace Green Recycling, Inc."), election of six directors, and adoption of a 2026 Equity Incentive Plan. The company received 9,029 redemption requests from shareholders (approximately 0.09% of shares) conditioned upon deal closure, and deposited $271.48 to extend the business combination deadline by one month to October 14, 2026—representing the fourth of nine permitted extensions. Investors should note the deal is on track to close but requires additional funding confirmation, and the repeated use of extension mechanisms may signal financing challenges or execution delays.